AI Article Synopsis
- Enzymatic nanoreactors were developed by encapsulating the enzyme galactose-1-phosphate uridylyl-transferase (GALT) into plant virus capsids using a self-assembly method.
- The goal was to create virus-like nanoparticles for enzyme-replacement therapy to treat classic galactosemia, with evaluated encapsulation efficiency and catalytic activity showing a 16% activity rate compared to the free enzyme.
- The nanoreactors demonstrated the ability to be taken up by various cell lines, particularly hepatocytes, highlighting their potential for therapeutic applications in classic galactosemia treatment.
Article Abstract
Enzymatic nanoreactors were obtained by galactose-1-phosphate uridylyl-transferase (GALT) encapsulation into plant virus capsids by a molecular self-assembly strategy. The aim of this work was to produce virus-like nanoparticles containing GALT for an enzyme-replacement therapy for classic galactosemia. The encapsulation efficiency and the catalytic constants of bio-nanoreactors were determined by using different GALT and virus coat protein ratios. The substrate affinity of nanoreactors was slightly lower than that of the free enzyme; the activity rate was 16 % of the GALT free enzyme. The enzymatic nanoreactors without functionalization were internalized into different cell lines including fibroblast and kidney cells, but especially into hepatocytes. The enzymatic nanoreactors are an innovative enzyme preparation with potential use for the treatment of classic galactosemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cmdc.202000999 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Results of the ACTION-Galactosemia Kids Study to Evaluate the Effects of Govorestat in Pediatric Patients with Classic Galactosemia.
J Clin Pharmacol
November 2024
Applied Therapeutics Inc., New York, NY, USA.
Article Synopsis
- A study called ACTION-Galactosemia Kids evaluated the effects of govorestat, a drug for Classic Galactosemia, on children aged 2-17 by comparing it to a placebo over 18 months.
- Govorestat showed a significant and lasting reduction in plasma galactitol levels, leading to stabilization or improvement in various clinical measures like behavior and daily living skills, while the placebo group showed decline.
- Despite its benefits, govorestat did not show improvements in speech or gross motor skills, and both the drug and placebo groups experienced similar rates of adverse effects, indicating it is safe and well tolerated.
Monosaccharides improve symptoms of an animal model for type III galactosemia, through the activation of the insulin pathway.
Biomed Pharmacother
December 2024
Centro Andaluz de Biología del Desarrollo (CABD) - Universidad Pablo de Olavide (UPO), Departamento de Biología Molecular e Ingeniería Bioquímica, UPO/CSIC/JA, Sevilla 41013, Spain. Electronic address:
Type III galactosemia is characterized by the inability to metabolize galactose due to deficiency of the UDP-galactose-4-epimerase (GALE) gene, which catalyzes the interconversion of UDP-Galactose and UDP-Glucose. Additionally, GALE interconverts UDP-N-Acetylgalactosamine and UDP-N-Acetylglucosamine. These four sugars are needed for glycosylation of biomolecules.
View Article and Find Full Text PDFSingle-nucleus and spatial transcriptomics of paediatric ovary: Molecular insights into the dysregulated signalling pathways underlying premature ovarian insufficiency in classic galactosemia.
Clin Transl Med
October 2024
Division of Pediatric and Adolescent Gynecology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA.
Article Synopsis
- - Classic galactosemia (CG) is linked to mutations in the GALT gene and leads to early ovarian insufficiency (POI) in 80% of women due to a decrease in ovarian reserve, though the underlying mechanisms are still unclear.
- - This study utilized advanced techniques like single-nucleus RNA sequencing to analyze ovary biopsies from prepubertal girls with CG, revealing seven key cell types and identifying disruptions in gene expression related to stress responses and cell survival.
- - The research highlighted significant changes in signaling pathways associated with ovarian function, indicating increased cellular stress and damage in primordial follicles, which could explain accelerated follicular loss in CG patients.
Clinical and biochemical evolution after partial dietary liberalization of two cases of galactosemia due to galactose mutarotase deficiency.
BMC Pediatr
September 2024
Diagnosis and Treatment Unit of Congenital Metabolic Diseases (UDyTEMC), Clinical University Hospital of Santiago de Compostela. National Reference Center for Metabolic Diseases (C.S.U.R.), Santiago de Compostela, Spain.
Article Synopsis
- The study presents a rare case of two 9-year-old twins with galactose mutarotase (GALM) deficiency who have remained asymptomatic, even after gradually reintroducing galactose into their diet after a period of strict dietary restriction.
- Initial detection was through newborn screening, leading to biochemical normalization after dietary adjustments; the genetic analysis revealed a complete deletion of a specific exon in the GALM gene.
- The findings suggest that dietary liberalization may not negatively affect health in GALM deficiency, prompting further exploration into dietary management for this condition.
Social cognition, psychosocial development and well-being in galactosemia.
Orphanet J Rare Dis
September 2024
Univ. Savoie Mont Blanc, Univ. Grenoble Alpes, LIP/PC2S, Grenoble, 38000, France.
Background: Classic galactosemia is a rare inherited metabolic disease with long-term complications, particularly in the psychosocial domain. Patients report a lower quality of social life, difficulties in interactions and social relationships, and a lower mental health. We hypothesised that social cognition deficits could partially explain this psychological symptomatology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!